RUNX2 and lymphoma: These are chemically diverse but act as substrate competitive inhibitors, inhibiting p53 monomethylation in vitro.44 Our initial studies with the lead compound AZ50545 showed no discernible activity against RUNX2/MYC lymphoma lines but were not available to us for in vivo use.